|Elimination half-life||4-7 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||371.27 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. There was some interest in its use in the treatment of treatment-resistant schizophrenia.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|